hyperCORE International, a strategic scaling platform that helps clinical research sites and organizations grow through partnership, has announced the election of new officers. Jeffrey Smyth will serve as President, Seneca Harrison as Vice President, and Claxton Copeland as Secretary, while Dustin Owen continues as Treasurer. The appointments signal a renewed focus on serving two distinct audiences through one platform: clinical research site networks seeking growth without losing independence, and contract research organizations (CROs) needing efficient access to experienced sites.
The leadership changes come as hyperCORE sharpens its mission to help partners scale. For site networks, hyperCORE provides the relationships, resources, and operational collaboration needed to expand reach, strengthen sponsor relationships, and build sustainable organizations. For CROs, the platform offers a single point of contact to a growing network of high-performing research sites, with rapid feasibility turnaround of 48 to 72 hours, broad U.S. geographic coverage, and expanded patient access.
Newly elected President Jeffrey Smyth expressed gratitude for the confidence placed in him, noting that the camaraderie across the network positions the group well for continued growth. "I step into this role with excitement as we scale our collective impact for CROs and patients," Smyth said. His remarks underscore the dual benefit of the platform: helping sites thrive while giving CROs a trusted connection to the patients and investigators their studies require.
Nicholas Focil, former President, reinforced the organization's simple purpose: "We help our partners scale." For site networks, that means giving exceptional organizations the support to grow on their own terms. For CROs, it means one reliable connection to the sites and patients their studies need. Focil emphasized that strong leadership is essential to that mission, and welcomed the new executive team.
The newly elected officers bring complementary expertise and strategic leadership to guide hyperCORE's continued evolution. Their collective experience will be critical as the organization strengthens partnerships and supports sustainable growth across its network. The current class of partner site networks includes Empathx Clinical Research, FOMAT Medical Research, Optimal Research Sites, QCR Network, and TrueBlue Clinical Research. Alumni include Lynd Clinical (formerly ARC), Avacare (formerly Benchmark Clinical Research), Flourish Research (formerly CSP & CTT), Centricity Research (formerly IACT Health, LMC Manna, Aventiv, and Lucas Research), and most recently, Alcanza Clinical Research.
For CROs, hyperCORE's value proposition is compelling. The network brings together more than 50 sites, 120+ principal investigators, and experience across more than 25 therapeutic areas and multiple trial phases, with access to more than 3.4 million patients. This scale enables CROs to streamline site access, accelerate feasibility, and broaden geographic reach across the United States. By providing one strategic connection to a growing network of experienced, high-performing sites, hyperCORE reduces the administrative burden on CROs and helps bring trials to patients faster.
The election of new officers is more than a procedural step; it is a strategic move to ensure hyperCORE can deliver on its promise to both site networks and CROs. As the clinical research landscape becomes increasingly complex, platforms that offer flexibility, independence, and efficient access to patients will be essential. hyperCORE International is positioning itself as a key enabler of that future, and with its new leadership team in place, it aims to scale its impact for partners and patients alike. For more information, visit hyperCORE International.
